Abstract
The Rosalind Franklin Society (RFS), in partnership with Mary Ann Liebert, Inc., publishers, enthusiastically congratulate our distinguished recipient of the 2022 annual
Dr. Laura Sepp-Lorenzino is an incredible woman from Argentina, and has helped the field a tremendous amount. She has served as a great role model for women and minorities on the pharma/biotech area in the field, and has served Nucleic Acid Therapeutics as a reviewer, author, and editorial board member.
Biosketch
Laura Sepp-Lorenzino, PhD, is chief scientific officer and executive vice president at Intellia Therapeutics, a leading clinical-stage genome editing company developing novel, potentially curative medicines leveraging CRISPR-based technologies. In addition to her extensive experience in nucleic acid therapies, Sepp-Lorenzino has expertise in oncology drug discovery and development acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as an assistant attending molecular biologist at Memorial Sloan Kettering Cancer Center. She received her professional degree in biochemistry from the University of Buenos Aires, Argentina, and both her MS and PhD in biochemistry from New York University. Sepp-Lorenzino is a member of the board of directors of Taysha Gene Therapies, the Alliance for Regenerative Medicine, and the Oligonucleotide Therapeutics Society and sits on the scientific advisory boards of Thermo Fisher Scientific, the UK Nucleic Acid Therapy Accelerator, and Arsenal Capital Partners. She is a member of the editorial board of Nucleic Acid Therapeutics.